Blood Collection of Patient Presenting in the ED and Prescribed a BNP
NCT ID: NCT02614209
Last Updated: 2016-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2015-05-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED
NCT00587938
Utility of Serial BNP Levels in Emergency Department CHF
NCT00534066
BNP Testing in Patients With SOB on Presentation to ED
NCT00163709
Prehospital Triage of Patients With Severe Shortness of Breath Using Biomarkers
NCT02050282
Exploring the Relationship Among BNP, Fluid Status and Acute Kidney Injury in Critically Ill Patients
NCT02095275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Stored specimens for future use in BNP assay development.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
In Vitro diagnostic tests
Prospective blood collection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to understand and willing to provide informed consent
* Present in to ED
* BNP test requested
Exclusion Criteria
* Unable to provide informed consent
* Not presenting to ED
* hemolyzed sample
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fujirebio Diagnostics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diana Dickson, RAC
Role: STUDY_DIRECTOR
Fujirebio Diagnostics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Maryland
Baltimore, Maryland, United States
Henry Ford Health System
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDI-120
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.